Adaptive Biotechnologies Corporation (NASDAQ:ADPT) highlighted updated National Comprehensive Cancer Network, or NCCN, multiple myeloma guidelines on September 17. According to the announcement, the recommendations specifically name clonoSEQ and expand testing time points to include annual assessments during maintenance and testing after later treatment lines.
The update strengthens the case for monitoring minimal residual disease, or MRD, the small amounts of cancer remaining after treatment. Preferred sensitivity is one cancer cell in one million cells, with one in 100,000 the recommended minimum. For investors, the opportunity is higher testing frequency across a patient’s treatment journey.
Bull Case
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) already has commercial momentum. Second-quarter clonoSEQ volume increased 43% year over year to 36,111 tests delivered. MRD business revenue rose 33% to $66.2 million, and management raised full-year MRD revenue guidance to $268 million to $278 million in July.
Those results predate the September announcement. They provide a baseline for assessing whether broader recommendations produce additional adoption.
Annual maintenance testing could create repeat orders from patients already using clonoSEQ. Recommendations covering later treatment lines, including CAR T-cell therapy, also create opportunities to maintain testing relationships as care changes. If clinicians incorporate these assessments into routine workflows, revenue growth could benefit from both new patients and more tests per existing patient.
Medicare already covers clonoSEQ for multiple myeloma. That provides an established reimbursement foundation, while more explicit clinical recommendations could support discussions with physicians and payers.
Bear Case
The guidelines also permit multicolor flow cytometry. Being the only assay named gives clonoSEQ visibility, but does not make it the exclusive testing option.
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) still needs recommendations to translate into completed, reimbursed tests. The guidance concerns bone-marrow-based assessments, making sample collection and clinical scheduling relevant to repeat testing. Physician judgment, patient circumstances, and payer rules will influence actual utilization.
Existing Medicare coverage does not establish payment for every recommended test under every insurance plan. Higher volume will create more value if realized reimbursement remains attractive and laboratory costs grow more slowly than revenue.